Skip to content

Evaluation of Two Levels of Frequency of Repositioning in the Reduction of Pressure Ulcers

Evaluation of the Efficacy of Two Levels of Frequency of Repositioning in Adults Hospitalized in Intensive Care Units, in the Reduction of Pressure Ulcers: A Randomized Cluster Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04604665
Acronym
PENFUP-2
Enrollment
3300
Registered
2020-10-27
Start date
2021-04-10
Completion date
2023-12-10
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Brief summary

PENFUP FASE 2, It is a multicenter study by parallel conglomerates, planned in order to evaluate the efficacy between two levels of frequency of postural change in intensive care units for adults of hospitals in various regions of Colombia.

Detailed description

Taking into account a design effect of 6.7, Investigators planned to include 150 participants from each ICU. Investigators did calculate that a total of 22 ICUs are required, in which 11 will be assigned to the low frequency and 11 will be assigned to a high frequency group of postural change until obtaining a total of 1,650 patients in each arm of the study and a total of 3,300 participants in the study.

Interventions

OTHERHigh frequency postural change

Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs.

OTHERConventional care

Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.

Sponsors

Universidad Autónoma de Bucaramanga
CollaboratorOTHER
Fundación Cardioinfantil Instituto de Cardiología
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Telephone randomization Random numbers centers Blinded for analyst and researchers

Intervention model description

Clinical trial, randomized, pragmatic, of parallel groups (1: 1), by clusters, blinded for the collection of information, sending, and in the evaluation of outcomes.

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* The ICU manage adult patients, over 18 years of age, with any type of emphasis (surgical, medical, neurological, or mixed); * Patients are admitted in critical condition (with life support); * The director accepts the commitment of the care assigned in the randomization (for a period of 3 months).

Exclusion criteria

* Intermediate care units in which patients mobilize themselves. * Covid patients or other patients exposed to different mobilization patterns (e.g., 12 hours prone vs 12 supine)

Design outcomes

Primary

MeasureTime frameDescription
The incidence (incidence rata ration) of new pressure ulcers in each Intensive Care Unit (ICU) 1 month after admissionThe number of pressure injuries at any stage, new acquired in the ICU after admission per 1,000 patient days in the ICU.

Secondary

MeasureTime frameDescription
Risk index (HR) and time to event of Pressure ulcers of the patients1 month safter admissionHazard ratio and tiem to event of PUs of patients included in the repositioning group with the lowest frequency compared to the group of patients included by intervention group in the development of the first PU during their stay in the ICU.
Security outcomes1 month after admissionSecondary safety outcomes: includes possible complications associated with postural changes: permanent or sporadic changes in ventilatory parameters (hypoxemia), hemodynamic changes (tachycardia, hypertension); events such as acute respiratory failure; or cardiogenic shock, pneumonia.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026